Last reviewed · How we verify
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development. Also known as: Menactra®.
At a glance
| Generic name | Menactra®: Polysaccharide Diphtheria Toxoid Conjugate |
|---|---|
| Also known as | Menactra® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (PHASE3)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menactra®: Polysaccharide Diphtheria Toxoid Conjugate CI brief — competitive landscape report
- Menactra®: Polysaccharide Diphtheria Toxoid Conjugate updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
What is Menactra®: Polysaccharide Diphtheria Toxoid Conjugate?
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Menactra®: Polysaccharide Diphtheria Toxoid Conjugate?
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Menactra®: Polysaccharide Diphtheria Toxoid Conjugate also known as anything else?
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate is also known as Menactra®.
What development phase is Menactra®: Polysaccharide Diphtheria Toxoid Conjugate in?
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate is in Phase 1.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: Menactra®
- Compare: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate vs similar drugs
- Pricing: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate cost, discount & access